CCL5 and cancer: These cells are also able to activate CD8+ cytotoxic T cells (35), which are the most potent anticancer immune effectors and constitute the foundation of current effective cancer immunotherapies (36) through the secretion of the chemokines previously listed (CCL2, CCL3, CCL4, CCL5 and CXCL10) (37).